Früher|Nächster

Bu Zhong Yi Qi Tang über den Nrf2/ROS/PERK/CHOP-Weg verbessert die Spannung des endoplasmatischen Retikulums, um die Platinresistenz bei nicht-kleinzelligen Lungenkrebstumoren zu überwinden

  • role： First author第一作者
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

  • Email：1197386342@qq.com
  • Introduction：李贺，硕士，从事以脾论治肺癌顺铂耐药分子机制研究，E-mail：1197386342@qq.com
LI He,  
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

LIU Yuetong,  
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

HUANG Jingyi,  
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

MU Qirui,  
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

LIU Chunying,  
  • role： Corresponding author通信作者
  • Affiliation：

    College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China

  • Email：gaoyuan.laury@163.com
  • Introduction：高原，博士，教授，从事以脾论治肺癌顺铂耐药分子机制研究，E-mail：gaoyuan.laury@163.com
GAO Yuan*

Resümee

Das Ziel dieser Studie ist es, die molekularen Mechanismen zu untersuchen, durch die Bu Zhong Yi Qi Tang die Platinresistenz von Platinresistenten Zellen des nicht-kleinzelligen Lungenkrebses (A549/DDP) verbessert, indem es den Nrf2 / reaktiven Sauerstoff (ROS) / Proteinkinase aktiviertes Ribosomales Protein (PERK) / Proteinhomolog des CCAAT-Enhancer-Bindungsproteins (CHOP)-Weg zur Verbesserung des endoplasmatischen Retikulumstresses reguliert. Wir haben auch gezeigt, wie das Nrf2/ROS/PERK/CHOP-Supplement, das Bu Zhong Yi Qi Tang folgt, die Spannung des endoplasmatischen Retikulums durch Manipulation des endoplasmatischen Retikulums verbessern kann.

Schlüsselwort

Bu Zhong Yi Qi Tang / nicht-kleinzelliger Lungenkrebs / Chemotherapieresistenz / endoplasmatischer Retikulumstress / reaktiver Sauerstoff

References

  1. 1.
    WANG Z，WU L，LI B，et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer： A multicenter randomized phase Ⅲ trial （CHOICE-01）［J］. J Clin Oncol，2023，41（3）：651-663.
  2. 2.
    WATHONI N，PULUHULAWA L E，JONI I M，et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer［J］. Drug Deliv，2022，29（1）：2959-2970.
  3. 3.
    MATHIEU L N，LARKINS E，SINHA A K，et al. FDA approval summary： Atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage Ⅱ to ⅢA NSCLC［J］. Clin Cancer Res，2023，29（16）：2973-2978.
  4. 4.
    WANG D，ZHAO C，XU F，et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2［J］. Theranostics，2021，11（6）：2860-2875.
  5. 5.
    MU Q R， FU Q Z， LIU C Y， et al. Mechanism study of Buzhong Yiqitang-containing serum on Wnt/β-catenin signaling pathway in A549/DDP cells to improve cisplatin resistance ［J］. Lishizhen Med Mater Med Res，2021，32（8）：1818-1821.
  6. 6.
    HSIEH C H，HSIEH H C，SHIH F S，et al. An innovative Nrf2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment［J］. Theranostics，2021，11（14）：7072-7091.
  7. 7.
    SÁNCHEZ-ORTEGA M，CARRERA A C，GARRIDO A. Role of Nrf2 in lung cancer［J］. Cells，2021，10（8）：1879.
  8. 8.
    FU D，WANG C，YU L，et al. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling［J］. Cell Mol Biol Lett，2021，26（1）：26.
  9. 9.
    LI D，HONG X，ZHAO F，et al. Targeting Nrf2 may reverse the drug resistance in ovarian cancer［J］. Cancer Cell Int，2021，21（1）：116.
  10. 10.
    HUANG W，WEN F，GU P，et al. The inhibitory effect and mechanism of Yi-qi-hua-yu-jie-du decoction on the drug resistance of gastric cancer stem cells based on ABC transporters［J］. Chin Med，2022，17（1）：93.
  11. 11.
    ZHANG Z，TAN Y，HUANG C，et al. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target［J］. E Bio Med，2023，89：104483.
  12. 12.
    LI H X，WANG T H，WU L X，et al. Role of Keap1-Nrf2/ARE signal transduction pathway in protection of dexmedetomidine preconditioning against myocardial ischemia/reperfusion injury［J］. Biosci Rep，2022，42（9）：BSR20221306.
  13. 13.
    TIAN Y，LI Y，LIU J，et al. Photothermal therapy with regulated Nrf2/NF-κB signaling pathway for treating bacteria-induced periodontitis［J］. Bioact Mater，2021，9：428-445.
  14. 14.
    MOU Q R， LIU C Y， WANG Z， et al. Molecular mechanism of Buzhong Yiqi decoction combined with cisplatin improves drug resistance of A549/DDP cells by regulating Wnt/β-catenin signaling pathway ［J］. Chin J Immunol，2023，39（5）： 961-965，972.
  15. 15.
    LI H， MOU Q R， WANG Z， et al. Molecular mechanism of Buzhong Yiqi decoction in coordination with Siβ-catenin in intervention against cisplatin resistance in lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway ［J］. J Chongqing Med Univ，2024，49（2）：147-152.
  16. 16.
    MOU Q R， LI H， LIU Y T， et al. Buzhong Yiqitang regulates apoptosis via Nrf2/ROS pathway to alleviate cisplatin resistance in A549/DDP cells ［J］. Chin J Exp Tradit Med Form，2024，30（1）：95-102.
  17. 17.
    GENESTRA M. Oxyl radicals， redox-sensitive signalling cascades and antioxidants［J］. Cell Signal， 2007，19（9）：1807-19.
  18. 18.
    ESMAEILI Y，YARJANLI Z，PAKNIYA F，et al. Targeting autophagy， oxidative stress， and ER stress for neurodegenerative disease treatment［J］. J Control Release，2022，345：147-175.
  19. 19.
    CHEN P，ZHONG X，SONG Y，et al. Triptolide induces apoptosis and cytoprotective autophagy by ROS accumulation via directly targeting peroxiredoxin 2 in gastric cancer cells［J］. Cancer Lett，2024，587：216622.
  20. 20.
    WANG A Q， SUN G P. Role and research progress of endoplasmic reticulum stress in anti-tumor therapy ［J］. Chin Pharmacol Bull，2021，37（12）：1643-1647.
  21. 21.
    MA K，VATTEM K M，WEK R C. Dimerization and release of molecular chaperone inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response to endoplasmic reticulum stress［J］. J Biol Chem， 2002，277（21）：18728-35.
  22. 22.
    HAN J，BACK S H，HUR J，et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death［J］. Nat Cell Biol，2013，15（5）：481-490.
  23. 23.
    LI H， YU D， MOU Q R， et al. Effects of Buzhong Yiqi decoction medicated serum combined with cisplatin on Nrf2， PRX1，SOD and GPX4 protein in human lung adenocarcinoma A549/DDP cells ［J］. Int J Tradit Chin Med，2024，46（5）：607-613.
  24. 24.
    LAHIRI A，MAJI A，POTDAR PD，et al. Lung cancer immunotherapy： Progress， pitfalls， and promises［J］. Mol Cancer，2023，22（1）：40.
  25. 25.
    HERBST RS，MORGENSZTERN D，BOSHOFF C. The biology and management of non-small cell lung cancer［J］. Nature，2018，553（7689）：446-454.
  26. 26.
    FU K，XIE F，WANG F，et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance［J］. J Hematol Oncol，2022，15（1）：173.
  27. 27.
    ROSSI A，DI MAIO M. Platinum-based chemotherapy in advanced non-small-cell lung cancer： Optimal number of treatment cycles［J］. Expert Rev Anticancer Ther，2016，16（6）：653-660.
  28. 28.
    DASARI S，TCHOUNWOU P B. Cisplatin in cancer therapy： Molecular mechanisms of action［J］. Eur J Pharmacol，2014，740：364-378.
  29. 29.
    WU J，LIN Z. Non-small cell lung cancer targeted therapy： Drugs and mechanisms of drug resistance［J］. Int J Mol Sci，2022，23（23）：15056.
  30. 30.
    WANG Y， ZHANG L， HUANG S M， et al. Discussion on the effects of tumor-associated macrophages polarization on lung cancer based on the TCM Yin-Yang theory ［J］. Chin J Inf Tradit Chin Med，2024，31（7）：14-19.
  31. 31.
    LI D Y. Differentiation of endogenous and exogenous diseases ［M］. Beijing：China Medical Science Press，2011， 15-16.
  32. 32.
    QIAN J N， SUN B Y， HU H Y. Clinical and basic research progress of Buzhong Yiqi decoction in treatment of malignant tumor diseases ［J］. J Hebei Tradit Chin Med，2021，36（5）：59-64.
  33. 33.
    WANG R，LIANG L， MATSUMOTO M，et al. Reactive oxygen species and Nrf2 signaling，friends or foes in cancer？［J］. Biomolecules，2023，13（2）：353.
  34. 34.
    TOSSETTA G，MARZIONI D. Natural and synthetic compounds in ovarian cancer： A focus on Nrf2/KEAP1 pathway［J］. Pharmacol Res，2022，183：106365.
  35. 35.
    HE F，ANTONUCCI L，KARIN M. Nrf2 as a regulator of cell metabolism and inflammation in cancer［J］. Carcinogenesis，2020，41（4）：405-416.
  36. 36.
    SZCZESNY-MALYSIAK E，STOJAK M，CAMPAGNA R，et al. Bardoxolone methyl displays detrimental effects on endothelial bioenergetics， suppresses endothelial ET-1 release， and increases endothelial permeability in human microvascular endothelium［J］. Oxid Med Cell Longev，2020，2020：4678252.
  37. 37.
    CHEN X，CUBILLOS-RUIZ J R. Endoplasmic reticulum stress signals in the tumour and its microenvironment［J］. Nat Rev Cancer，2021，21（2）：71-88.
  38. 38.
    SCHÖNTHAL A H. Endoplasmic reticulum stress： Its role in disease and novel prospects for therapy［J］. Scientifica （Cairo），2012，2012：857516.
  39. 39.
    KHANNA M，AGRAWAL N，CHANDRA R，et al. Targeting unfolded protein response： A new horizon for disease control［J］. Expert Rev Mol Med，2021，23：e1.
  40. 40.
    UBEDA M，WANG X Z，ZINSZNER H，et al. Stress-induced binding of the transcriptional factor CHOP to a novel DNA control element［J］. Mol Cell Biol，1996，16（4）：1479-1489.
  41. 41.
    RAO J，ZHANG C，WANG P，et al. C/EBP homologous protein （CHOP） contributes to hepatocyte death via the promotion of ERO1α signalling in acute liver failure［J］. Biochem J，2015，466（2）：369-378.
  42. 42.
    CHEN B L，SHEU M L，TSAI K S，et al. CCAAT-enhancer-binding protein homologous protein deficiency attenuates oxidative stress and renal ischemia-reperfusion injury［J］. Antioxid Redox Signal，2015，23（15）：1233-1245.
  43. 43.
    SIMMEN T，LYNES E M，GESSON K，et al. Oxidative protein folding in the endoplasmic reticulum： Tight links to the mitochondria-associated membrane （MAM）［J］. Biochim Biophys Acta，2010，1798（8）：1465-1473.
  44. 44.
    GROSS E，SEVIER C S，HELDMAN N，et al. Generating disulfides enzymatically： Reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p［J］. Proc Natl Acad Sci USA，2006，103（2）：299-304.
  45. 45.
    RAMMING T，OKUMURA M，KANEMURA S，et al. A PDI-catalyzed thiol-disulfide switch regulates the production of hydrogen peroxide by human Ero1［J］. Free Radic Biol Med，2015，83：361-372.
  46. 46.
    KORENNYKH A，WALTER P. Structural basis of the unfolded protein response［J］. Annu Rev Cell Dev Biol，2012，28：251-277.
  47. 47.
    MICHEL S，CANONNE M，ARNOULD T，et al. Inhibition of mitochondrial genome expression triggers the activation of CHOP-10 by a cell signaling dependent on the integrated stress response but not the mitochondrial unfolded protein response［J］. Mitochondrion，2015，21：58-68.
  48. 48.
    LIU Z，SHI Q，SONG X，et al. Activating transcription factor 4 （ATF4）-ATF3-C/EBP homologous protein （CHOP） cascade shows an essential role in the ER stress-induced sensitization of tetrachlorobenzoquinone-challenged PC12 cells to ROS-mediated apoptosis via death receptor 5 （DR5） signaling［J］. Chem Res Toxicol，2016，29（9）：1510-1518.
  49. 49.
    CHEN Y，GUI D，CHEN J，et al. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside Ⅳ is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats［J］. Cell Physiol Biochem，2014，33（6）：1975-1987.
  50. 50.
    WANG L，HU R，DAI A. Curcumin increased the sensitivity of non-small-cell lung cancer to cisplatin through the endoplasmic reticulum stress pathway［J］. Evid Based Complement Alternat Med，2022，2022：6886366.

Lesen Sie die ganze Passage

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website